An observational study in Covid19, sponsored by University of Bergen. Recruiting at 1 site in Norway. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-04-19.
Sponsored by University of Bergen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in COVID-19 with a site in Norway — 3 open to participants now, 7 under way, 1 of them phase 3. COVID-19 · Norway.
Among the 47 studies in COVID-19 with a site in Norway, this one is the 7th largest by planned enrollment of the 23 observational ones that give a count, is one of 10 that started in 2021, is one of 23 observational ones, and was the 24th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →3 of the 47 studies in COVID-19 with a site in Norway are open now. Recruiting first, the newest first:
University Hospital of North Norway · Sites in Norway
Ages 18–65
ANRS, Emerging Infectious Diseases · Sites in Norway, France, Italy
Ages 16+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2020; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 302 across the 24 interventional studies, 860 across the 23 observational. Of the 32 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 47 have an industry lead sponsor. The 10 most frequent:
University of Bergen is the lead sponsor of 143 studies on the registry; 19 are open to participants now.
University of Bergen has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies in COVID-19 with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04514003Sykehuset TelemarkThe Corona and COVID-19 Study in Telemark and Agder | 2026-12-31 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 47 studies in COVID-19 with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has been intensified by no population-based immunity to the severe acute respiratory disease coronavirus 2 (SARS-CoV2) and initially lack of effective treatments or vaccines available to mitigate the pandemic. Currently, two COVID-19 vaccines are available for vaccination in Europe through conditional marketing authorisation granted by the European Medicines Agency and further vaccine will be licensed. These vaccines have shown good vaccine efficacy in phase 3 vaccine trials. We will recruit subjects who will be prioritised for vaccination with the primary aim of comparing the immune responses after COVID-19 vaccination and natural SARS-CoV-2 infection. In Western Norway we have recruited cohorts of health care workers and patients infected with SARS-CoV-2 and will extend to COVID-19 vaccinees. Demographic, clinical data and repeated blood samples will be collected to evaluate the complications and kinetics, duration and breadth of the immune responses comparing natural infection to vaccination.
The primary aim of this study is
Comparator group: patients with natural SARS-CoV-2 infection Vaccine groups: Health care workers and high-risk population groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500-1000 health care workers prioritized for early vaccination
Biological: covid-19 vaccine
2000 individuals in patient populations prioritized for vaccinations
Biological: covid-19 vaccine
vaccination
immune responses
spike antibody response to SARS-CoV-2
Time frame: 2 months to 3 years
Duration and breadth of B- cell responses
compare serological and memory B cells after vaccination to natural infection
Time frame: 2 months to 3 years
Duration and breadth of T cell responses
compare T cell responses after vaccination to natural infection
Time frame: 2 months to 3 years
Plan to share: Undecided — To be developed
Started Jan 2021 (actual). Primary completion is estimated for Dec 2024, 47 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 47 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.